FR2483780A1 - Vaccin vivant contre l'echtyma du mouton et de la chevre, administrable par voie sous-cutanee ou intradermique - Google Patents
Vaccin vivant contre l'echtyma du mouton et de la chevre, administrable par voie sous-cutanee ou intradermique Download PDFInfo
- Publication number
- FR2483780A1 FR2483780A1 FR8012642A FR8012642A FR2483780A1 FR 2483780 A1 FR2483780 A1 FR 2483780A1 FR 8012642 A FR8012642 A FR 8012642A FR 8012642 A FR8012642 A FR 8012642A FR 2483780 A1 FR2483780 A1 FR 2483780A1
- Authority
- FR
- France
- Prior art keywords
- virus
- echtyma
- vaccine
- kaolin
- sheep
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 27
- 241001494479 Pecora Species 0.000 title claims abstract description 15
- 241000283707 Capra Species 0.000 title claims abstract description 7
- 241000700605 Viruses Species 0.000 claims abstract description 20
- 210000002966 serum Anatomy 0.000 claims abstract description 11
- 244000309466 calf Species 0.000 claims abstract description 10
- 239000005995 Aluminium silicate Substances 0.000 claims abstract description 9
- 235000012211 aluminium silicate Nutrition 0.000 claims abstract description 9
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 8
- 239000002671 adjuvant Substances 0.000 claims abstract description 7
- 210000000663 muscle cell Anatomy 0.000 claims abstract description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 4
- 239000011707 mineral Substances 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 9
- 230000003612 virological effect Effects 0.000 claims description 8
- 239000001963 growth medium Substances 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 238000005096 rolling process Methods 0.000 claims description 2
- 241000287828 Gallus gallus Species 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 abstract description 2
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 2
- 229960005030 other vaccine in atc Drugs 0.000 abstract 1
- 239000002356 single layer Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000283903 Ovis aries Species 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000295644 Staphylococcaceae Species 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
- RPABDKTXMKOGKI-OYTUFZPASA-N 6-methyl-n-[2-[(2s,5s,8s,11s,14s,17s,20s,23s)-8,11,14,20-tetrakis(2-aminoethyl)-5-[(1r)-1-hydroxyethyl]-17,23-bis(2-methylpropyl)-3,6,9,12,15,18,21,24-octaoxo-1,4,7,10,13,16,19,22-octazacyclotetracos-2-yl]ethyl]octanamide Chemical compound CCC(C)CCCCC(=O)NCC[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H]([C@@H](C)O)NC1=O RPABDKTXMKOGKI-OYTUFZPASA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 239000004187 Spiramycin Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229960001294 spiramycin Drugs 0.000 description 1
- 229930191512 spiramycin Natural products 0.000 description 1
- 235000019372 spiramycin Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24261—Methods of inactivation or attenuation
- C12N2710/24264—Methods of inactivation or attenuation by serial passage
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8012642A FR2483780A1 (fr) | 1980-06-06 | 1980-06-06 | Vaccin vivant contre l'echtyma du mouton et de la chevre, administrable par voie sous-cutanee ou intradermique |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8012642A FR2483780A1 (fr) | 1980-06-06 | 1980-06-06 | Vaccin vivant contre l'echtyma du mouton et de la chevre, administrable par voie sous-cutanee ou intradermique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2483780A1 true FR2483780A1 (fr) | 1981-12-11 |
| FR2483780B1 FR2483780B1 (OSRAM) | 1983-08-05 |
Family
ID=9242803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8012642A Granted FR2483780A1 (fr) | 1980-06-06 | 1980-06-06 | Vaccin vivant contre l'echtyma du mouton et de la chevre, administrable par voie sous-cutanee ou intradermique |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2483780A1 (OSRAM) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU456693B2 (en) * | 1970-10-09 | 1974-12-09 | Tasman Vaccine Laboratory Limited | Improvements; in virus vaccines |
-
1980
- 1980-06-06 FR FR8012642A patent/FR2483780A1/fr active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU456693B2 (en) * | 1970-10-09 | 1974-12-09 | Tasman Vaccine Laboratory Limited | Improvements; in virus vaccines |
Non-Patent Citations (1)
| Title |
|---|
| CA1970 * |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2483780B1 (OSRAM) | 1983-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0623167B1 (fr) | Preparation d'antigenes et de vaccins de virus de la mystery disease, antigenes et vaccins obtenus pour la prevention de cette maladie | |
| Nandi et al. | Bovine ephemeral fever: a review | |
| Mel et al. | Studies on vaccination against bacillary dysentery: 4. Oral immunization with live monotypic and combined vaccines | |
| CN103263666B (zh) | 猪圆环病毒2型、猪支原体肺炎二联灭活疫苗及其制备方法 | |
| PL145565B1 (en) | Method of obtaining a vaccine for therapeutically and prophylactically treating infections of respiratory tracts of humans | |
| Smith et al. | The chemical basis of the virulence of Brucella abortus: I. Isolation of Br. abortus from bovine foetal tissue | |
| US5165924A (en) | Serum-free, cell-free vaccine effective against pneumonic pasteurellosis in cattle | |
| Mel et al. | Studies on vaccination against bacillary dysentery: 1. Immunization of mice against experimental Shigella infection | |
| JP2001520205A (ja) | ネオスポラワクチン | |
| Smith et al. | The Chemical Basis of the Virulence of Brucella abortus: IV. Immunogenic Products from Br. abortus Grown in vivo and in vitro | |
| US4472378A (en) | Live vaccine for the prevention of salmonellosis in water fowl, a process for making and applying the same | |
| SAKAZAKI et al. | Serological studies on the Cloaca (Aerobacter) group of enteric bacteria | |
| FR2483780A1 (fr) | Vaccin vivant contre l'echtyma du mouton et de la chevre, administrable par voie sous-cutanee ou intradermique | |
| Shope | The effect of hemophilus influenzae suis vaccines on swine influenza | |
| US4229434A (en) | Vaccine for prophylaxis of trichophytosis in horse and method of preparing same | |
| Smith et al. | The weak immunogenicity of Fusobacterium necrophorum | |
| Mankiewicz et al. | Mycobacteriophages isolated from human sources | |
| RU2076735C1 (ru) | Живая рекомбинантная вакцина гепатита в на основе вируса осповакцины для перорального применения и способ ее получения | |
| FR2479000A1 (fr) | Vaccin contre la brucellose, maladie du betail | |
| KR101210082B1 (ko) | 돼지 다발성 장막염 예방용 백신 조성물 및 그 제조방법 | |
| EP0106831B1 (fr) | Souches modifiées du virus de la diarrhée virale bovine, leur préparation et vaccins les contenant | |
| NO118229B (OSRAM) | ||
| Sokhey et al. | Casein hydrolysate cholera vaccine | |
| Smith | The basis of immunity to anthrax | |
| FR2506615A1 (fr) | Vaccin contre les brucelloses humaines et son procede de fabrication |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |